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INTRODUCTION
HIV-1, being a lentivirus, encodes the enzyme reverse transcriptase (RT) for copying the viral RNA into a viral dsDNA 1 . The DNA is integrated into the host cell chromosome by integrase, another viral enzyme. The DNA polymerization activity of RT is currently targeted by two classes of drugs that inhibit the enzyme by two distinct mechanisms.
Non-nucleoside RT inhibitors (NNRTIs) bind to a hydrophobic pocket adjacent to the polymerase active site of RT 2, 3 , and an NNRTI functions as an allosteric inhibitor by perturbing the conformational state of an RT/nucleic acid complex [4] [5] [6] [7] . In contrast, a nucleoside analog RT inhibitor (NRTI) binds as dNTP mimic, and is catalytically incorporated into the primer DNA strand by RT. All NRTIs act as DNA chain terminators because they lack a 3'-OH preventing the incorporation of next nucleotide.
Currently, five NNRTIs and eight NRTIs are approved anti-AIDS drugs. RT-inhibiting drugs are widely used in combinations with protease, integrase, and viral entry inhibitors for treating HIV-1 infections. Like other types of HIV drugs, the effectiveness of an RT inhibitor is compromised by side effects and emergence of drug resistance upon long-term use. Various RT mutations emerge to confer resistance to NRTIs and NNRTIs [8] [9] [10] . RT confers NRTI resistance primarily (i) by exclusion or discrimination of an NRTI triphosphate from a dNTP (M184V/I and K65R are examples of exclusion mutations) and (ii) by excision, which removes an incorporated NRTI from the primer terminus by pyrophosphorolysis. The AZT (1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl) oxolan-2-yl]-5-methylpyrimidine-2,4-dione) resistance mutations [D67N, K70R, L210W, T215Y/F and K219Q/E 11 , also known as AZTr, excisionenhancing mutations (EEMs), or thymine analog mutations (TAMs)] facilitate binding of an ATP molecule to RT as a pyrophosphate donor for excision [12] [13] [14] .
Periodically, new drugs are needed in the pool of available drugs for improving the treatment options for patients facing adverse side effects or resistance challenges to current drugs. Effective (i) nucleotide-competing RT inhibitors (NcRTIs) that compete with dNTP binding 15, 16 , or (ii) pyrophosphate mimics that would prevent pyrophosphorolysis/excision have potential for being developed as new classes of RT-inhibiting drugs. Foscarnet (phosphonoformic acid, PFA), a pyrophosphate mimic, is used to treat cytomegalovirus (CMV) eye infection in patients with AIDS. PFA is also used to treat herpes simplex virus (HSV) infections of the skin and mucous membranes in immunocompromised persons 17,18 when they do not respond to other therapies. HIV-1 RT, like other DNA polymerases, is inhibited by PFA at an IC 50 in the sub-micromolar range 19 . PFA retains its potency against HIV-1 RT carrying NRTI and NNRTI resistance mutations 20, 21 . PFA is not, however, routinely used clinically to treat HIV infection, likely due to a modest inhibitory effect. Optimization and elaboration of the PFA scaffold may help in developing more potent RT-specific drugs for treating HIV-1 infection.
Based on biochemical studies [22] [23] [24] and a crystal structure of PFA in complex with an engineered chimeric DNA polymerase (UL54) of CMV 25 , PFA is expected to bind HIV-1 RT mimicking the β, γ−pyrophosphate moiety of a dNTP. Our earlier attempts to obtain a crystal structure of an RT/DNA/PFA complex were not successful using either cross-linked or non-cross-linked RT/DNA N-site complexes 14, 26 . A primary challenge was to stabilize an N-site RT/nucleic acid binary complex to which PFA is expected to bind 24 . Using a modified SELEX (selective evolution of ligands by exponential enrichment) approach, template-primer sequences that bind HIV-1 RT with high affinity were selected 27 . Further modification of these sequences led to the construction of a 38-mer hairpin DNA aptamer (apt-DNA) that bound HIV-1 RT with very high affinity 28 . This aptamer binds RT as a 15 base-pair duplex extending from the polymerase active site towards the RNase H domain, a threedeoxythymidine hairpin loop proximal to the RNase H domain, and a five-nucleotide 5'-overhang 29 .
Here we demonstrate that the RT/apt-DNA complex is catalytically active, permitting the binding of AZTTP as a dNTP analog and subsequently incorporating AZTMP at the 3'-end (Figure 1 ) in crystals. However, translocation of the DNA was restricted by the aptamer hairpin that is locked against the RNase H domain of RT, and this stable N-site complex in crystals permitted the binding of PFA as a pyrophosphate mimic. The RT/apt-DNA P-site complex permitted the binding of α-T-CNP 16 by coordinating with both catalytic metal ions. The binding of α-T-CNP and PFA to RT reveals two distinct conformations of the polymerase active site with different chelating environments for designing novel RT inhibitors.
RESULTS AND DISCUSSION
AZTTP binding and incorporation into apt-DNA by RT in crystals. The structure of the RT/apt-DNA complex (I) was recently reported at 2.3 Å resolution, revealing that the binding mode of the aptamer is similar to that of previously reported cross-linked RT/DNA complexes at and near the polymerase active site 29 . RT/DN A cross-linking were performed in conjunction with catalytic addition of one dideoxynucleotide at the primer 3'-end 30, 31 . In fact, most reported DNA polymerase pre-catalytic complex structures have been determined with 3'-dideoxyterminated nucleic acid. In contrast, the complex I has a 3'-OH group that is positioned at the polymerase active site for binding and catalytic addition of the next nucleotide, which is a dTTP or related analog. Ca 2+ ions are not efficient cations for DNA polymerization by RT. We soaked AZTTP and CaCl 2 into crystals of I for the formation of a ternary complex without incorporation. As described in the experimental section, a short (5-minute) soak formed a ternary RT/DNA/AZTTP (II) complex in the crystal, and the structure of the complex was determined at 3.3 Å resolution (SI Table 1 ). The AZTTP binds at the N site in a mode that is analogous to the previously obtained mode of binding in RT/dsDNA/AZTTP (or dTTP) complex structures (Figures 2A & B ) 6, 30 . A Ca 2+ ion is present at the metal B site and chelates one oxygen from each of the three phosphates of AZTTP; no ion is present at the A site. Even though the 3'-end of apt-DNA had an OH group present for incorporation of the incoming AZTMP, the use of Ca 2+ ions was not efficient for carrying out the catalysis in the crystal within the 5-minute soaking time. Soaking a crystal in 2.8 mM AZTTP with 25 mM MgCl 2 for 10 minutes, however, confirmed our hypothesis that the RT/apt-DNA complex is indeed catalytically active by incorporating an AZTMP at the 3'-end of the apt-DNA ( Figures  2C & D) . Serendipitously, the incorporated AZTMP does not translocate from the N site to the P site because the DNA hairpin is locked against the RNase H domain of RT at the opposite end, preventing the sliding of DNA in the crystal. The crystal packing analysis (SI Figure  1) did not indicate any noticeable interaction of apt-DNA with symmetry related molecules. Unlike a typical RT/DNA complex, which can be highly dynamic in solution 32 , the RT/apt-DNA apparently forms a stable complex with enhanced protein-nucleic acid interactions. The RT/apt-DNA-AZTMP (III) structure represents a state of RT/DNA complex following catalytic incorporation of a dNTP that precedes translocation. In this pre-translocation N-site state (III), the Mg 2+ ions are dissociated from the polymerase active site after the catalytic addition of AZTMP, and two catalytic aspartates D110 and D186 are pointing away from nucleic acid at the active site. The phosphate oxygens of the newly formed phosphodiester bond are in close proximity to both carboxyl oxygens of the third catalytic aspartate D185 (Figure 2D) .
In a typical RT/nucleic acid complex, this congregation of negatively charged groups would either (i) repel to facilitate the nucleic acid translocation or (ii) attract cations to stabilize the N state and facilitate pyrophosphorolysis, as discussed below.
PFA binding to the RT/apt-DNA complex. PFA as a pyrophosphate mimic is expected to bind and stabilize an N-site complex 22, 23 . Complex III in the crystal was used to obtain the structure of the RT/DNA/PFA (IV) complex. We soaked crystals of complex III in a solution containing 5 mM PFA and 25 mM MgCl 2 for 10 minutes to enable formation of the RT/DNA/PFA ternary complex IV (SI Table 1 ). Compared to complex III, in which the catalytic ions were dissociated from the polymerase active site, the binding of PFA importantly recruited both catalytic Mg 2+ ions A and B to the polymerase active site in IV (Figures 3A & B) . One oxygen each from the phosphate and carboxyl groups of PFA chelate metal B. Chelation of the phosphate of AZTMP, the main-chain carbonyl oxygen of V111, and one side-chain oxygen each from the catalytic residues D110 and D185 complete the octahedral coordination for metal B. Apart from the metal ion chelation, the conformation of RT did not undergo any significant alteration in changing from III to IV upon PFA binding. In comparison to the binding of a dNTP, the phosphate and the carboxyl oxygens of PFA approximately substitute for the chelating oxygens of β,γ-pyrophosphate, respectively; however, the positions of the chelating atoms are not superimposable ( Figure 3C ). The mode of chelation of PFA to RT is switched when compared with that observed in the structure of engineered chimeric DNA polymerase UL54 complex (Figures 3D &  E ) 25 . This preferred orientation of PFA in the RT complex is apparently steered by a network of interactions of the phosphate group with RT beyond the metal interaction site. The interactions are (i) with the main-chain amide group of D113, adjacent to the polymerase active site and (ii) a salt bridge between the two non-chelating oxygens of the phosphate group of PFA and the guanidinium group of R72 ( Figure 3F) ; R72 is a highly conserved amino acid residue that is essential for polymerization 33 . Additionally, the side chain of K65 interacts with the non-chelating oxygen of the carboxyl group of PFA. PFA has been reported to facilitate the removal of AZTMP from the 3'-end of the DNA primer 34 . Positioning of the phosphate group of PFA near the phosphodiester bond of incorporated AZTMP in complex III may facilitate the excision only when the phosphate group of PFA is oriented in-line as an excision agent. However, the PFA orientation in III is not appropriate to initiate excision despite the close proximity of the phosphate group to the phosphodiester bond ( Figure 3C ). PFA resistance. Commonly observed RT mutations associated with PFA resistance are K65R, W88G/S, E89K, A114S, S117T, Q161L, M164I, and Q161L/H208Y 22, [35] [36] [37] . Residue K65 interacts with PFA in structure IV. The K65R mutation influences the positioning of amino acids R65 and R72 38 , and this structural rearrangement would interfere with the observed interactions of the two amino acid residues K65/R72 with PFA (Figures 3F & G) . Residue A114 is positioned adjacent to the phosphate group of PFA or the β−phosphate group of a dNTP substrate, and the side chain of S114 in an A114S mutant RT would perturb the position and/or charge distribution of the phosphate group. The remaining RT mutations are located away from PFA, and would interfere indirectly with PFA binding presumably by reducing the stability of the N-site complex or by interfering with the positioning of the two metal ions. The amino acid residue stretch 88-95 interacts with the template strand adjacent to the polymerase active-site, and mutations in this stretch affect fidelity of RT 39 . Mutations at positions 88 and 89 are likely to perturb the positioning of the template strand.
Most of the PFA-resistance mutations reduce the pyrophosphorolysis by RT, i.e., the mutations either directly interfere with the binding of pyrophosphate or indirectly reduce the stability of an N-site RT complex. Thereby, the PFA-resistance mutations reduce the ability of RT to excise AZTMP and, consequently, improve AZT sensitivity even in the presence of AZT-resistance mutations (EEMs). Structurally, it has been shown that the EEMs primarily enhance the binding affinity of ATP as a pyrophosphate donor. As expected, comparison of the complex IV with the structure of the RT/DNA/AZTppppA excision product complex 14 shows that PFA would interfere with the binding/positioning of the pyrophosphate moiety of an ATP. In such a scenario, the pyrophosphate moiety would not be able to reach the active site even if EEMs enhance the binding of the base-ribose moiety of ATP to RT.
Binding of α-T-CNP. Unlike PFA, the NcRTI α-CNP binds as a dNTP mimic at the N site. There are important differences, however, in the interactions and chelation geometry for α-T-CNP compared to dTTP (or AZTTP). Recently, we reported the structure of α-T-CNP in complex with a cross-linked RT/DNA 16 , in which cation A was not present at the polymerase active site primarily due to the use of a dideoxy-terminated primer. The structure of the RT/apt-DNA/α-T-CNP complex (V) determined at 2.75 Å resolution (SI Table1), however, confirm the presence of both metal ions at the polymerase active site and reveals the complete coordination of the inhibitor ( Figure 4A ). The structures IV and V, both being in one crystal form, provide a direct comparison of the binding of α-T-CNP and PFA to RT ( Figure 4B) ; the first one as a dNTP-and the second one as a pyrophosphate-competing inhibitor, respectively. PFA binds only when the primer terminus is at the N site, and α-T-CNP binds only when the primer terminus is at the P site, i.e., binding of the two inhibitors is mutually exclusive. However, each of the two inhibitors is expected to complement AZT in inhibiting RT because either one can bind when AZT is a chain terminator. AZT and PFA have earlier been demonstrated to act synergistically against HIV in cell culture 19,40,,41 and AZTTP has also been claimed to synergistically inhibit HIV-1 RT when combined with PFA 41 , but only at their IC 90 or IC 95 concentrations, whereas antagonistically or additively inhibiting the enzyme when combined at IC 50 or IC 75 concentrations, respectively. These observations demonstrate the complexity of drug combinations 42 , and also revealed a mutually exclusive inhibition of HIV-1 RT by AZTTP and PFA. Potential antiviral synergy between AZT (or PFA) and α-CNPs could not be tested since the current α-CNPs are not efficiently taken up by HIV-infected cells. Therefore, combinations of AZTTP with PFA, AZTTP with T-α-CNP, and PFA with T-α-CNP have been investigated for their inhibition of RT activity over a broad range of inhibitor concentrations (SI Figure 2) . No dramatic differences were observed in the degree of increased potencies of the anti-HIV-1 RT activity when any of the inhibitors was combined with one of the other inhibitors. The combination index (CI) versus fractional inhibition values, and normalized isobolograms (SI Figure 3) for the three different inhibitor combinations revealed additive to modest synergistic activities in all three cases, with somewhat lesser effect for the PFA/T-α-CNP combination. It should, however, be noticed that the RT assays were conducted in a cell-free system under artificial conditions. These results may reflect the dynamic states of an RT/DNA complex in solution that did not permit trapping the RT/DNA/PFA complex when the special apt-DNA was not used in the assay. Improved inhibitors with higher binding affinity may form more stable complexes.
Drug design. The active-site region of an enzyme in general is less susceptible to mutation, and therefore represents a highly valuable target for drug discovery. Information on the precise metal chelation geometry 43 and the surrounding environment can help in designing target-specific inhibitors. Derivatives of 4-chlorophenyl hydrazine mesoxalic acid (CPHM) have been identified as translocation inhibitors 44, 45 . Analogous to PFA, CPHM compounds are predicted to preferentially bind to N-site complexes of RT. Despite both inhibitors chelating the polymerase active site cations, the interactions of the distinct side groups with RT define their respective binding affinity and impacts of resistance mutations; K65R mutation favors CPHM binding and develops resistance to PFA. K65R mutation forms a guanidinium platform with R72 38 , and the platform presumably stacks favorably with the aromatic side group of CPHM. The malonate group of CPHM might chelate Mg 2+ ions of an N complex in a mode analogous to the structurally observed mode of chelation of a malonatecontaining NcRTI to the P complex (PDB ID 5HLF) 46 . In the context of antiviral activity, PFA inhibits HIV, whereas, the malonate-containing NcRTI and CPHM fail to exhibit antiviral response presumably because of their inability to penetrate the cell wall. The comparison of PFA and CPHM in inhibiting RT suggests that chemical modifications of the compounds binding to the N or P complex could be exploited for improved RT binding and cellular uptake.
Additionally, the individual conformational states of the active site of RT can ideally be targeted and trapped by small molecules. Active-site metal-chelating inhibitors, such as the HIV-1 integrase-inhibiting drugs raltegravir, elvitegravir, and dolutegravir, chelate the catalytic metal ions of the intasome complex to block strand transfer 47, 48 . A systematic elaboration from the metal-chelating diketo acid moiety helped gain specificity and efficacy even in the absence of any three-dimensional structural information 47 . In an analogous platform, knowledge of the binding and chelation of PFA or α-T-CNP at the polymerase active site of RT provides opportunities for developing new RT-inhibiting drugs. In agreement with the existing biochemical data, the structural data show that PFA binding stabilizes the N-site complex, and PFA binding would inhibit pyrophosphorolysis as a pyrophosphatecompeting inhibitor. Mutations that would reduce the binding of PFA are likely to reduce the binding of a pyrophosphate donor and excision. Therefore, either the presence of PFA or PFAresistance mutations, in general, suppresses AZT resistance both in viral and enzymatic studies 37, 49 . RT has to compromise its activity for developing resistance to PFA, however, the binding affinity of PFA to RT is modest due to the lack of RTspecific interactions. The structure of IV reveals the conformational state of RT and the molecular interactions between RT and PFA. Chemical elaboration of the PFA backbone aided by knowledge of the structure may lead to improved pyrophosphate-mimicking inhibitors. Combining structural features of α-T-CNP/AZTTP at the Nsite and PFA ( Figure 4B ) may help to develop novel high-affinity NcRTIs that can exhibit antiviral activity.
CONCLUSIONS
A special 38-mer DNA aptamer permitted obtaining the crystal structure of a highly stable HIV-1 RT/DNA complex (I) 29 , and the crystals were used to obtain the structures with bound AZTTP (II), AZT-MP incorporated at the N site (III), and PFA bound to an N-site complex (IV) (Figure 1) . Also, a structure of the NcRTI, α-T-CNP (V), chelating both catalytic Mg 2+ ions at the polymerase active site of RT, is reported here for the first time. This series of structures illuminate multiple conformational states of the polymerase site that HIV-1 RT would undertake for processing nucleotide addition or pyrophosphorolysis. The structural knowledge of these distinct states of the active site may enhance understanding the molecular mechanisms of various drugresistance mutations and help in targeting DNA polymerization by new classes of active-sitechelating inhibitors.
MATERIALS AND METHODS
Reverse transcriptase assay with homopolymeric template-primers. HIV-I RT assays were carried out in the presence of the artificial homopolymeric template-primer poly(A)dT [12] [13] [14] [15] [16] [17] [18] (oligo(dT), Pharmacia, Uppsala, Sweden). To prepare the template-primer for the RT inhibition experiments, 0.15 mM poly(A) was mixed with an equal volume of 0.0375 mM oligo(dT). The reaction mixture (50 µl) contained 50 mM TrisHC1 pH 7.8, 5 mM dithiothreitol, 300 mM glutathione, 500 µM EDTA, 150 mM KCl, 5 mM MgCl 2 , 1.25 µg of bovine serum albumin, an appropriate concentration of the tritium-labeled substrate [CH 3 -3 H]dTTP (2 µCi/assay; 2 µM), a fixed concentration of the template-primer poly(A).oligo(dT) (0.015 mM), 0.06% Triton X-100, 10 µl of AZTTP, T-α-CNP and/or PFA inhibitor solution (containing various concentrations of the compounds or dual combinations thereof), and 1 µl of the HIV-1 RT preparation. The reaction mixtures were incubated at 37 °C for 30 minutes, at which time 100 µl of calf thymus DNA (150 µg/ml), 2 ml of Na 4 P 2 0 7 (0.1 M in 1 M HCl), and 2 ml of trichloroacetic acid (10% v/v) were added. The solutions were kept on ice for 30 minutes, after which the acid-insoluble material was washed and analyzed for radioactivity. The inhibition data were processed using Crystallography. RT purification and crystallization with apt-DNA were carried out using earlier described experimental conditions 29 . Crystals of RT/apt-DNA (I) complex were soaked in the crystallization solution containing 25 mM CaCl 2 and 2.8 mM AZTTP for 5 minutes for the formation of RT/apt-DNA/AZTTP ternary complex (II). Crystals of I were soaked with 25 mM MgCl 2 and 2.8 mM AZTTP for 10 minutes, and the condition was suitable for catalytic incorporation of AZTMP at the 3'-end of the apt-DNA by RT to form the RT/AZT-terminated apt-DNA Nsite complex (III). Crystals of III were then soaked in a solution containing 25 mM MgCl 2 and 5 mM PFA for 1 hour for the formation of RT/apt-DNA/PFA ternary complex (IV). Crystals of I were soaked in a solution containing 25 mM MgCl 2 and 2 mM α-T-CNP for the formation of RT/apt-DNA/α-T-CNP ternary complex (V). All crystal soaking solutions contained 10% (w/v) PEG 8000, 25 mM Bis-tris propane pH 6.8, 75 mM Bis-tris propane pH 7.4, 50 mM ammonium sulfate, 5% (v/v) glycerol, and 5% (w/v) sucrose. The cryoprotectant solutions in which the crystals were dipped prior to flash cooling were made from the respective soaking solution by increasing the glycerol concentration to 25% (v/v). X-ray diffraction data were collected using synchrotron beam lines; the initial structures were solved using the structure of RT/apt-DNA complex (PDB ID 5D3G ) as the starting model. The structures were refined using Phenix 51 and the model building was carried out using Coot 52 . The crystallographic data and refinement statistics are listed in SI Table 1 , and the coordinates and structure factors were deposited in the PDB under accession codes 5I42, 5I3U, 5HP1, and 5HRO for structures II to V, respectively.
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